Magikle Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 16-11-2024
- Paid Up Capital ₹ 0.90 M
as on 16-11-2024
- Company Age 25 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.50 Cr
as on 16-11-2024
- Satisfied Charges ₹ 2.61 Cr
as on 16-11-2024
- Revenue 3.10%
(FY 2023)
- Profit -42.24%
(FY 2023)
- Ebitda 27.76%
(FY 2023)
- Net Worth 0.30%
(FY 2023)
- Total Assets -0.27%
(FY 2023)
About Magikle Pharma
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹18.50 Cr. The company has closed loans amounting to ₹2.61 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suneeti Soni, Nikhil Soni, and Neelam Nanda serve as directors at the Company.
- CIN/LLPIN
U24239DL1999PTC101544
- Company No.
101544
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Sep 1999
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Magikle Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suneeti Soni  | Director | 14-Sep-1999 | Current |
| Nikhil Soni | Additional Director | Current | |
| Neelam Nanda | Additional Director | Current |
Financial Performance of Magikle Pharma.
Magikle Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.1% increase. The company also saw a substantial fall in profitability, with a 42.24% decrease in profit. The company's net worth moved up by a moderate rise of 0.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Magikle Pharma?
In 2023, Magikle Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Mar 2024 | ₹16.50 Cr | Open |
Oriental Bank Of Commerce Creation Date: 07 May 2013 | ₹2.00 Cr | Open |
Oriental Bank Of Commerce Creation Date: 27 Aug 2013 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Magikle Pharma?
Magikle Pharma has a workforce of 8 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Magikle Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Magikle Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
